

# Diaphragm Muscle Contraction Decrease in a Mouse Model of Ovalbumin-Induced Allergic Airway Inflammation

Kazunobu Yamaguchi<sup>1,2</sup>, Chiyohiko Shindoh<sup>3</sup> and Masahito Miura<sup>1\*</sup>

<sup>1</sup>Department of Clinical Physiology, Health Sciences, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan

<sup>2</sup>Medical Department, AstraZeneca. K.K., Osaka 530-0011, Japan

<sup>3</sup>Medical Examination Center, Sendai Open Hospital, Sendai 983-0824, Japan

\*Corresponding author: Masahito Miura, Department of Clinical Physiology, Health Sciences, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aobaku, Sendai 980-8575, Japan; E-mail: [mmiura@med.tohoku.ac.jp](mailto:mmiura@med.tohoku.ac.jp)

Received date: September 4, 2017; Accepted date: September 7, 2017; Published date: September 14, 2017

Copyright: © 2017 Yamaguchi, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

**Objective:** We investigated diaphragm contractile and inflammatory properties of mice with OVA sensitization and challenge.

**Methods:** BALB/c mice were sensitized to OVA by intraperitoneal (i.p.) injection at 0 and 7 days, and challenged with aerosolized OVA on 21, 22, and 23 days (O/O group). Budesonide/Formoterol combination was inhaled on days 21, 22, and 23 before OVA challenge on those same days (O/OC group). Control mice were sensitized and challenged with an aerosolized saline (O-group). The diaphragm contractile and inflammatory properties were measured on day 24. NOS activity in the diaphragm muscle was evaluated by NADPH diaphorase staining. IL-4 and IL-13 levels of BALF, as well as lung tissue and diaphragm muscle homogenates were measured by ELISA.

**Results:** Force-frequency (F/f) curves of O/O and O/OC shifted downward in comparison with O- ( $p < 0.05$ ). NADPH diaphorase staining results of O/O and O/OC showed a significantly higher density compared with O-. The IL-4 level of diaphragm muscle homogenates increased significantly in the O/O compared with the O- and O/OC.

**Conclusions:** OVA sensitization and challenge decreased diaphragm muscle contraction, increased NOS activity, IL-4 levels of diaphragm in a mouse model. Budesonide/Formoterol combination could protect diaphragm muscle weakness and inflammation. According to the traditional concept of the contemporary Immunology, neither autoimmune diseases nor allergic diseases can be cured completely. Nevertheless, a fortunate coincidence led me to discovery of a novel concept that eliminations of the causes of these diseases are possible. In other words, combinations of pathogenic antibodies with responsible cells, namely, cytolytic T lymphocytes in cases of autoimmune diseases and mast cells in cases of allergic diseases, can be decomposed by replacing the pathogenic antibodies with non-specific antibodies. In more detail, intradermal injections with a non-specific antigen preparation induce production of non-specific antibodies in the body of the patient. Repetitions of the injections bring about an accumulation of them. Accumulated non-specific antibodies will occupy most of the receptors on the surface of responsible cells. When the accumulation reaches the sufficient level, virtually no pathogenic antibodies would remain on the receptors. That is, no causes of the diseases remain. Naturally, where there is no cause, there is no disease. Details are demonstrated elsewhere.

**Keywords:** OVA; Diaphragm muscle; NOS; ICS/LABA; Inflammation

**Abbreviations:** TNF-: Tumor Necrosis Factor-alpha; Th2: T helper-2; IL: Interleukin; NO: Nitric oxide; BAL: Broncho Alveolar Lavage; OVA: Ovalbumin; IP: Intraperitoneal; PBS: Phosphate Buffered Saline; F/f: Force-frequency; NADPH: Nicotinamide Adenine Dinucleotide Phosphate; NOS: Nitric Oxide Synthase; AU: Arbitrary Unit; Inos: Inducible NO Synthase; TLR: Toll-like Receptor.

## Introduction

Asthma is a chronic airway disease characterized by airway inflammation, narrowing, hyper responsiveness, and remodeling [1]. It is well known that inspiratory resistive breathing reduces diaphragm muscle contractility, and bronchoconstriction leads to diaphragm muscle fatigue in an asthma patient [2,3]. And it is well known that

airway inflammation, bronchoconstriction and airway hyper responsiveness increase in an ovalbumin (OVA) sensitized and challenged mice [4-6]. However, research has not yet shown clearly whether OVA sensitization and challenge reduces diaphragm muscle contractility, ICS/LABA combination protects diaphragm muscle weakness or not. In this study we investigated diaphragm muscle contractility and inflammatory profile of OVA sensitized and challenged mice and the effect of ICS/LABA.


## Methods

### Animal preparation

61 male BALB/c mice weighing 26.0 0.6 g at 6-8 weeks of age (CLEA Japan, Inc., Tokyo, Japan) were randomly divided into three groups-control group treated with saline (O- group), allergic group sensitized and challenged with OVA (O/O group), treatment group sensitized

and challenged with OVA plus Budesonide/Formoterol inhalation (O/OC group). The experimental protocol was approved by the Ethics Committee for Animal Experimentation at Tohoku University (2013-Idou-441).

O/O and O/OC mice were sensitized with an intraperitoneal (i.p.) injection of 100 µg Chicken OVA (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and 1 mg aluminum hydroxide in 20 µl phosphate-buffered saline (PBS) on days 0 and 7. O/O and O/OC mice were challenged for 30 minutes with aerosolized 1% OVA using a nebulizer PARI-emotion (PARI Japan, Osaka, Japan) on days 21, 22 and 23. O/OC mice were inhaled Budesonide (LKT Laboratories, Inc., St Paul, USA) 36 µg and Formoterol (LKT Laboratories, Inc., St Paul, USA) 1 µg combination with Lactose 163 µg by Dry powder insufflator model DP-4 (Penn-Century, Inc., Glenside, USA) and air pump model AP-1 (Penn-Century, Inc., Glenside, USA) on days 21, 22, and 23 before OVA challenge on those same days. O-mice were administrated 20 µl PBS by an i.p. injection on day 0, 7 and administrated for 30 minutes with PBS on days 21, 22 and 23 (Figure 1).



### Measurements of muscle contraction

Muscle contraction properties were measured on Day 24. Mice of each group were sacrificed by decapitation under deep anesthesia and diaphragm muscle was resected to evaluate the muscle contraction. Muscle strips were dissected from the right and left hemi diaphragm of each animal and mounted in separate organ baths containing Krebs-Henseleit solution oxygenated with a 95% O<sub>2</sub> and 5% CO<sub>2</sub> gas mixture (37.0 ± 0.5°C, pH 7.40 ± 0.05). Both muscle strips were simultaneously stimulated with supramaximal currents of 200 to 250 mA through an isolation unit (SS-302; Nihon Kohden Co., Tokyo, Japan) and driven by a stimulator (SEN-3201; Nihon Kohden Co., Tokyo, Japan). These electrical stimulations were controlled by computer. The elicited tensions were measured by a force transducer (UL-100GR; Minebea Co., Nagano, Japan). The length of each muscle strip was altered by moving the position of the force transducer with a micrometer-controlled rack and pinion gear (accuracy of displacement, 0.05 mm; Mitsutoyo Co., Aichi, Japan) and measured with a micrometer in close proximity to the muscle.

The diaphragm force-frequency curves were assessed by sequentially stimulating muscles at 1, 10, 20, 30, 50, 70, 100 and 120 Hz. Each stimulus train was applied for 1 s, and adjacent trains were applied at 10-s intervals by computer. The tensions of the muscle strips were recorded by a thermal pen recorder (RECTI-HORIZ-8K; NEC San-ei, Tokyo, Japan). The force-frequency curves of the groups were

displayed as elicited tensions (N/cm<sup>2</sup>) versus stimulation frequencies (Hz). Twitch contraction was elicited by single pulse stimulation (0.2-m sec pulse duration) and twitch kinetics were assessed by twitch tension (TT; N/cm<sup>2</sup>), contraction time (CT; the time required to develop peak tension, m sec), and half-relaxation time (HRT; the time required for peak tension to decrease by 50%, m sec) during a single muscle contraction. Muscle fatigue was assessed through the rate of tension decrease over a 5-min period of rhythmic contraction, which was induced by applying trains of 20-Hz stimuli at a rate of 60 trains/min. Muscle fatigue was expressed as a percentage of the final tension (%) compared with initial tension. We determined according to a previously described method [7,8].

### NADPH diaphorase staining

Mice of each group were sacrificed by decapitation under deep anesthesia and diaphragm muscle was resected to evaluate a NOS activity by NADPH diaphorase staining [9,10]. The diaphragm was quickly excised, and the tissue pieces were frozen in O.C.T. Compound (Tissue-Tek; Sakura Fine technical Co., Ltd., Tokyo, Japan) in a thermos containing dry ice and acetone. Cryosections (10 µm in thickness) were cut from the diaphragm in the O.C.T. Compound. The histochemical procedure for NADPH diaphorase consisted of dipping the sections in freshly prepared 1.0 mM -NADPH (Oriental Yeast Co., Ltd., Tokyo, Japan) and 0.2 mM nitroblue tetrazolium (Wako Pharmaceutical Co., Osaka, Japan) in 100 mM tris-HCL buffer, pH 8.0, containing 0.2% Triton X-100 for 30 min at 37°C. The reactions were stopped by rinsing the sections in phosphate buffered saline (PBS). The sections were covered with a mixture of glycerol and PBS (2:1) and photographed by a microscope (Axiolab A1; Carl Zeiss MicroImaging GmbH, Göttingen, Germany) with a charge-coupled device camera (Axio Cam ERc 5S; Carl Zeiss MicroImaging GmbH, Göttingen, Germany). The mean density of the cross-sectional views of each muscle fiber was measured using image analyzer software (NIH Image, National Institutes of Health, Bethesda, MD, USA). More than 30 muscle fibers were counted in each photograph, and the densities were averaged and expressed in arbitrary units (a.u.). NADPH diaphorase staining was performed as described previously [7].

### Cytokines in BALF by ELISA

BALF, lung tissue and diaphragm muscle were collected to evaluate levels of IL-4 and IL-13 on day 24. Study mice were sacrificed under deep anesthesia, BALF, lung tissue and diaphragm muscle was collected. Lung tissue and diaphragm muscle were homogenized, and total protein from lung tissue and diaphragm muscle were extracted by a kit (Minute™, Invent Biotechnologies, Inc., Eden Prairie, MN, USA). Levels of IL-4 and IL-13 in BAL fluid, and total protein of lung tissue homogenates and diaphragm muscle homogenates were analyzed by ELISA using a Diaclone IL-4 mouse ELISA kit (Gen-Probe Diaclone SAS, Besancon, France) and a Diaclone IL-13 mouse ELISA kit (Gen-Probe Diaclone SAS, Besancon, France).

### Data analysis

Data were analyzed using JMP ver11.0 (SAS Institute, North Carolina, USA). Mean values of tensions for each frequency of force-frequency curves, twitch kinetics, fatigability, Levels of IL-4 and IL-13 were compared by 1-way ANOVA with Fisher's LSD post-hoc analysis.

## Results

### Muscle contraction

The force-frequency curve of OVA group O/O ( $14.6 \pm 1.5$  N/cm<sup>2</sup> peak) was significantly shifted downward compared with control group O- ( $18.5 \pm 1.9$  N/cm<sup>2</sup> peak) and OVA plus Budesonide/Formoterol inhalation group O/OC ( $18.8 \pm 1.3$  N/cm<sup>2</sup> peak) ( $p < 0.05$ , each) (Figure 2).




Figure 2: Changes in force-frequency curves of OVA group (O/O: closed circles), Budesonide/Formoterol inhalation group (O/OC: closed squares), control group (O-: open circles). # $p < 0.05$ .




Figure 3: Changes in (A) Twitch Tension, (B) Contraction Time, (C) Half Relaxation Time and (D) Fatigabilities of the O/O, O/OC and O- groups.




Figure 4: NADPH diaphorase staining of the O/O, O/OC and O- groups. \*\*\* $p < 0.001$

This result suggested that OVA sensitization and challenge decreased diaphragm muscle contraction and Budesonide/Formoterol inhalation protected diaphragm muscle weakness. There were no significant changes in TT, CT and HRT of twitch contraction and fatigability (Figure 3).

### NADPH diaphorase staining


NADPH diaphorase staining was used to detect NOS activity. The mean density of OVA group O/O ( $195.0 \pm 6.1$  a.u.) was significantly strengthened compared with control group O- ( $107.8 \pm 5.1$  a.u.) and OVA plus Budesonide/Formoterol inhalation group O/OC ( $71.3 \pm 4.4$  a.u.) ( $p < 0.001$ , each) (Figure 4).

This result indicate that OVA sensitization and challenge increased NOS activity compared with O- and Budesonide/Formoterol inhalation protected OVA induced NOS activity.

### Cytokines in BALF, lung tissue and diaphragm muscle homogenates by ELISA

*IL-4* and *IL-13* levels in BALF, in lung tissue homogenates and in diaphragm muscle homogenates were measured using *ELISA* for assessing inflammatory cytokines of Th2. Overall there was no significant difference between them in BALF and in lung tissue homogenates (Figures 5A and 5B). *IL-4* levels of O/O in diaphragm muscle homogenates was significantly increased compared with control group O- and OVA plus Budesonide/Formoterol inhalation group O/OC ( $p < 0.05$ , each) (Figure 5C).

This result indicates that OVA sensitization and challenge have inflammatory cytokine inductions of *IL-4* in diaphragm muscle of mice. These results suggested that NOS activity affected induction of Th2 cytokines in the diaphragm muscle.



**Figure 5:** (A) IL-4 levels and IL-13 levels in BALF; (B) IL-4 levels and IL-13 levels in lung tissue, (C) IL-4 levels and IL-13 levels of the O/O, O/OC and O- groups in diaphragm muscle. \* $p < 0.05$ .

## Discussion

The main findings of this study are: 1) OVA sensitized and challenged diaphragm muscle contraction was reduced; 2) OVA sensitization and challenge increased NOS activity in the diaphragm of mice; 3) OVA sensitization and challenge increased IL-4 in the diaphragm of mice; 4) Budesonide/Formoterol inhalation protected diaphragm muscle contractile dysfunction, OVA induced NOS activity and IL-4 in diaphragm muscle. F/f curve of OVA sensitized and challenged mice shift downward compared with control group. The implication is that OVA contribute to diaphragm muscle weakness. Although there has been no study that OVA affect the diaphragm muscle, it seems that mechanisms of diaphragm muscle contraction reduction are due to: 1) OVA increase resistive breathing of mice; 2) IL-4 is induced inside the diaphragm in response to resistive breathing; 3) iNOS is produced by IL-4; 4) muscle contraction is reduced by iNOS.

There were previously reported that OVA increased the breathing resistance of the mice [11], resistive breathing induced IL-4 expression in diaphragm muscle [12], Th2 cytokines such as IL-4 and IL-13 induce iNOS expression through the STAT-6 pathway [13-17], iNOS reduced diaphragm muscle contraction, inhibition of iNOS induction and inhibition of NOS activity prevented diaphragm muscle contractile dysfunction [18]. Study results of ours are in agreement with study that previously reported. Budesonide/Formoterol inhalation protected diaphragm muscle contractile dysfunction. We assume that

Budesonide/Formoterol reduce the resistive breathing through bronchodilation of Formoterol and anti-inflammatory effect in airway of Budesonide. In particular, airway edema caused by the continuation of inflammation is improved with Budesonide as an ICS, bronchoconstriction caused by airway remodeling and airway hypersensitivity are improved with Formoterol as a LABA. Hence Budesonide/Formoterol protect the weakness of diaphragm muscle contraction through prevent the induction of IL-4 and iNOS. Our results support previous findings indicating that OVA sensitization and challenge exacerbate the airway inflammation [4,19,20]. ICS and ICS/LABA are used as a first choice for asthma treatment around the world. The effectiveness of ICS and ICS/LABA for asthma treatment is supported in plural large clinical trials [21-29].

In conclusion, OVA sensitization and challenge led to diaphragm muscle weakness and Budesonide/Formoterol inhalation protected diaphragm muscle weakness. OVA sensitization and challenge increased IL-4 levels and NOS activity in the diaphragm muscle, Budesonide/Formoterol inhalation decreased IL-4 levels and NOS activity through bronchodilation of Formoterol and anti-inflammatory effect of Budesonide.

## Acknowledgements

Kazunobu Yamaguchi: Contributed to the design and coordination of the study, prepared the manuscript, and read and approved the final manuscript.

Masahito Miura: Contributed to preparing the manuscript, and read and approved the final manuscript.

Chiyohiko Shindoh: Contributed to preparing the manuscript, and read and approved the final manuscript.

## Disclosure

Kazunobu Yamaguchi is employee of AstraZeneca K.K. The authors report no other conflicts of interest in this work.

## References

- Ohta K, Ichinose M, Nagase H, Yamaguchi M, Sugiura H, et al. (2014) Japanese Guideline for Adult Asthma 2014. *Allergol Int* 63: 293-333.
- Roussos CS, Macklem PT (1977) Diaphragmatic fatigue in man. *J Appl Physiol Respir Environ Exerc Physiol* 43: 189-197
- Hill AR (1991) Respiratory muscle function in asthma. *J Assoc Acad Minor Phys* 2: 100-108.
- Renz H, Smith HR, Henson JE, Ray BS, Irvin CG, et al. (1992) Aerosolized antigen exposure without adjuvant causes increased IgE production and increased airway responsiveness in the mouse. *J Allergy Clin Immunol* 89: 1127-1138.
- Blyth DJ, Pedrick MS, Savage T J, Hessel EM, Fattah D (1996) Lung inflammation and epithelial changes in a murine model of atopic asthma. *Am J Respir Cell Mol Biol* 14: 425-438.
- Kung TT, Jones H, Adams GK, Umland SP, Kreutner W, et al. (1994) Characterization of a murine model of allergic pulmonary inflammation. *Int Arch Allergy Immunol* 105: 83-90.
- Shindoh C, Shishido R, Narumi N, Murai N, Miura M (2012) Inhalation of budesonide/formoterol increases diaphragm muscle contractility. *Allergol Int* 61: 439-449.
- Shindoh C, Dimarco A, Nethery D, Supinski G (1992) Effect of PEG-superoxide dismutase on the diaphragmatic response to endotoxin. *Am Rev Respir Dis* 145: 1350-1354.

9. Morris BJ, Simpson CS, Mundell S, Maceachern K, Johnston HM, et al. (1997) Dynamic changes in NADPH-diaphorase staining reflect activity of nitric oxide synthase: evidence for a dopaminergic regulation of striatal nitric oxide release. *Neuropharmacology* 36: 1589-1599.
10. Rebeck GW, Marzloff K, Hyman BT (1993) The pattern of NADPH-diaphorase staining, a marker of nitric oxide synthase activity, is altered in the perforant pathway terminal zone in Alzheimer's disease. *Neurosci Lett* 152: 165-168.
11. Blanchet MR, Israel-Assayag E, Cormier Y (2005) Modulation of airway inflammation and resistance in mice by a nicotinic receptor agonist. *Eur Respir J* 26: 21-27.
12. Vassilakopoulos T, Divangahi M, Rallis G, Kishta O, Petrof B, et al. (2004) Differential cytokine gene expression in the diaphragm in response to strenuous resistive breathing. *Am J Respir Crit Care Med* 170: 154-161.
13. Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, et al. (2000) Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. *J Immunol* 164: 5970-5980.
14. Guo FH, Uetani K, Haque S J, Williams BR, Dweik RA, et al. (1997) Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. *J Clin Invest* 100: 829-838.
15. Suresh V, Mih JD, George SC (2007) Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. *Am J Respir Cell Mol Biol* 37: 97-104.
16. Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, et al. (2008) IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. *Clin Exp Allergy* 38: 936-946.
17. Munakata M (2012) Exhaled nitric oxide (FeNO) as a non-invasive marker of airway inflammation. *Allergol Int* 61: 365-372.
18. Sambe A, Ungureanu-Longrois D, Danialou G, Lanone S, Benessiano J, et al. (1998) Role of nitric oxide on diaphragmatic contractile failure in *Escherichia coli* endotoxemic rats. *Comp Biochem Physiol A Mol Integr Physiol* 119: 167-175.
19. Lawrence TE, Millecchia LL, Frazer DG, Fedan JS (1997) Pulmonary dendritic cell distribution and prevalence in guinea pig airways: effect of ovalbumin sensitization and challenge. *J Pharmacol Exp Ther* 282: 995-1004.
20. Xu L, Olivenstein R, Martin JG, Powell WS (2000) Inhaled budesonide inhibits OVA-induced airway narrowing, inflammation, and cys-LT synthesis in BN rats. *J Appl Physiol* 89: 1852-1858.
21. Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, et al. (2000) Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. *Am J Respir Crit Care Med* 161: 1459-1464.
22. Chanez P, Karlstrom R, Godard P (2001) High or standard initial dose of budesonide to control mild-to-moderate asthma? *Eur Respir J* 17: 856-862.
23. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, et al. (2005) Daily versus as-needed corticosteroids for mild persistent asthma. *N Engl J Med* 352: 1519-1528.
24. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, et al. (1998) Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. *J Allergy Clin Immunol* 101: 457-463.
25. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *N Engl J Med* 337: 1405-1411.
26. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, et al. (2001) Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. *Am J Respir Crit Care Med* 164: 1392-1397.
27. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, et al. (2003) Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. *Chest* 123: 1480-1487.
28. Atienza T, Aquino T, Fernandez M, Boonsawat W, Kawai M, et al. (2013) Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results. *Respirology* 18: 354-363.
29. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, et al. (2006) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. *Lancet* 368: 744-753.